Press Releases - Sparc Life

2024 - 25

17 Dec

SPARC Announces Signing of Binding Letter of Intent with UCSF and Tiller Therapeutics for Pre-clinical Oncology Asset and Associated Intellectual Property

View More

13 Dec

SPARC to Provide Update on Clinical Programs and R&D Pipeline

View More

10 Apr

SPARC Announces Results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson’s Disease

View More
2023 - 24

4 Jan

SPARC to Present at the 42nd Annual J.P. Morgan Healthcare Conference

View More

2 Nov

SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB

View More

30 Oct

SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson’s Disease

View More

19 Oct

SPARC to Provide Update on Clinical Programs and R&D Pipeline

View More

13 July

FDA issues complete response letter for PDP-716 NDA due to inspection findings at third-party API manufacturing facility

View More
2022 - 23

18 Nov

SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures

View More

09 Nov

Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US

View More

29 Sep

SPARC to Provide Update on Clinical Programs and R&D Pipeline

View More
2021 - 22

10 Dec

SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting

View More

08 Dec

SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma

View More

03 Dec

SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target

View More

26 Nov

SPARC to Provide Update on Clinical Programs and R&D Pipeline

View More

14 May

SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension

View More
2020 - 21

14 Oct

SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery

View More

22 Sep

SPARC Licenses Commercialization Rights of ElepsiaTM XR to Tripoint Therapeutics

View More

19 Aug

SPARC to Provide Update on R&D Pipeline

View More

28 May

SPARC enters into a worldwide license agreement for SCD-044 with Sun Pharma

View More

13 Feb

SPARC to Provide Update on TaclantisTM NDA

View More
2019 - 20

19 Dec

SPARC acquires Bioprojet’s rights for SCD-044

View More

09 Dec

SPARC Provides Update on Paclitaxel Injection Concentrate for Suspension (PICS) Litigation

View More

05 Nov

SPARC Enters into a Licensing Deal with CMS

View More

22 Aug

SPARC to Provide Update on R&D Pipeline

View More

08 Jul

SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia

View More

01 Jul

SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

View More

13 Mar

HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration

View More
2018 - 19

03 Dec

Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

View More

26 Nov

SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension

View More

14 Sep

Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension

View More

10 Sep

Audio playback of Investors Presentation

View More

04 Jul

Update on R&D Pipeline

View More
2017 - 18

06 Oct

SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis

View More

14 Jun

SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)

View More
2016 - 17

26 Aug

Announcement – Receipt of reclassification approval from BSE

View More

25 Aug

Announcement – Receipt of reclassification approval from NSE

View More

25 Jul

Update on NCE and NDDS Programs

View More

18 Jul

SPARC Licenses ELEPSIATM XR (Levetiracetam ER Tablets) to Sun Pharma

View More
2015 - 16

31 Dec

Update on XELP ROST and Elepsia XRT

View More

25 Sep

SPARC Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA

View More

01 Aug

SPARC Receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

View More

09 Jun

SPARC Licenses Xelpros™ to Sun Pharma

View More

04 Mar

SPARC receives USFDA approval for ELEPSIA XR

View More
2014 -15

01 Dec

SPARC receives Complete Response Letter (CRL) from USFDA for Latanoprost NDA

View More

23 Jan

India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

View More

Copyright @ 2024. All Rights Reserved.

Follow Us :